Worse survival outcomes have been reported in BRCA2-mutated breast cancer (but not BRCA1) compared to sporadic cancers, independent of treatment, in some population-based studies, which seems to be due to adverse tumour characteristics [69]. This evidence concerns the gene BRCA2 and breast cancer.